NARB ProgramBackgrounds

National Advertising Review Board

The National Advertising Review Board (NARB) is the appellate body for the U.S. system of advertising industry self-regulation. Five-member NARB panels hear cases appealing an NAD or CARU decision and provide independent industry peer review, ensuring truthfulness and accuracy in national advertising and helping promote voluntary compliance of its decisions—a key pillar of industry self-regulation.

Program Impact

NARB, established in 1971 as a fair and impartial appellate body, reviews appealed NAD or CARU decisions. Nominated by various leading organizations in the advertising industry, NARB members are selected for their stature and experience in their fields. 

 

 

Truth & Transparency

When a competitor’s advertising harms consumer trust or threatens a company’s reputation and market share, the advertising self-regulatory system creates a level-playing field for business and helps ensure consumers receive truthful and accurate advertising.

Compliance

After a decision, NARB or the challenger can check in on whether the advertiser has made appropriate modifications to its advertising and has 10 days to respond. The case is closed if there is a good faith effort to bring their advertising into compliance.

Non-Compliance

In cases of lack of good faith efforts to modify or discontinue advertising as a result of a NARB decision, NARB will refer the case to an appropriate government agency, usually the Federal Trade Commission (FTC).
 

For the last 50 years in the advertising industry, companies have held each other to a higher standard. In response to the pressures and criticisms of consumerism that had mounted during the previous decade, in 1971 the advertising industry established the National Advertising Division (NAD) and National Advertising Review Board (NARB), the U.S. mechanism of independent self-regulation that has stood the test of time and technological innovation.

 

Visit NAD50th.org

Guidelines & Procedures


Any advertiser or challenger has the right to appeal NAD’s decision to NARB. An advertiser has an automatic right of appeal. A challenger must request permission to appeal from the NARB chair and explain why it believes there is a substantial likelihood NARB would come to a different conclusion on a case than NAD. 

 

News & Blog

Press Release

BBB National Programs Announces 98 Distinguished Panel Pool Members for 2024 National Advertising Review Board

McLean, VA – January 9, 2024 – BBB National Programs today announced the 98 panel pool members of the 2024 National Advertising Review Board (NARB), the appellate body for the U.S. advertising industry’s system of self-regulation. 

Read the Press Release
Press Release

BBB National Programs Announces 91 Distinguished Panel Pool Members for 2023 National Advertising Review Board

McLean, VA – January 10, 2023 – BBB National Programs today announced the 91 panel pool members of the 2023 National Advertising Review Board, the appellate body for the U.S. advertising industry’s system of self-regulation, selected for their stature and experience in their fields.

Read the Press Release

Misleading Health Claims in COVID-19 Advertising

Feb 17, 2021, 09:56 AM by Annie Ugurlayan, Assistant Director, and Laura Brett, Vice President, National Advertising Division
Truth in advertising is important to protect consumers and help level the playing field for fair competition in the marketplace. This core concept becomes especially important when advertising health-related products, including over-the-counter drugs and dietary supplements.

During the COVID-19 pandemic, there has been an explosion of challenges to health product advertisements that expressly or impliedly claim to protect consumers and their families from the coronavirus. Consumers rely on ads, especially those that claim a product will support their immune system or help ward off disease. When they hear these claims, they also expect that there is science that supports such claims. 

Truth in advertising is important to protect consumers and help level the playing field for fair competition in the marketplace. This core concept becomes especially important when advertising health-related products, including over-the-counter drugs and dietary supplements. 

COVID-19 has forced consumers to focus on their health and well-being, so it is no surprise that health-related advertising has also been a focus of competitor challenges at BBB National Programs this past year. Indeed, there has been a nearly 50 percent increase in competitor challenges concerning health-related advertising claims.

For example, there were multiple challenges to products touting health and wellness benefits for traditional over-the-counter drugs, as well as natural alternatives that purported to offer similar relief or alternative wellness benefits. Brands new to self-regulation participated in challenges, including makers of essential oils and natural cough remedies, both popular products in the burgeoning natural health and wellness marketplace.  

 

 

Many of these product claims about wellness benefits required a review of complex issues and science-heavy claim substantiation, an encouraging indicator that brands take seriously the requirement that health-related advertising claims be supported by competent and reliable scientific evidence. The resulting decisions provide guidance on crafting truthful and accurate advertising for consumers so that health-related advertising claims are supported by science and competitors play by the same set of rules.    

BBB National Programs’ National Advertising Division (NAD) and Direct Selling Self-Regulatory Council (DSSRC) have monitored the advertising landscape for decades, but during the COVID-19 pandemic, health-related claims, including those referencing the coronavirus, represented the greatest volume of challenges and cases received. 

Once the pandemic began, government agencies sprang into action. Both the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have issued dozens of warning letters since spring 2020 about express and implied claims that products can treat or prevent COVID-19.  

As the effects of the pandemic continue, NAD and DSSRC remain vigilant, with each increasing their monitoring for advertising touting COVID-19-related health benefits due to its prevalence. During 2020, 38 percent of NAD’s monitoring cases were brought against companies making health-related claims concerning their product’s ability to boost consumers’ immunity against, or otherwise protect them from, COVID-19. After releasing guidance for the direct-selling industry early in the year that urged caution regarding health-related claims made by direct sellers or their salesforces, DSSRC saw 98 COVID-19 related cases, primarily on social media platforms and primarily related to the dietary supplement industry.  

Hope is on the horizon, with virus case counts and deaths going down, and COVID-19 vaccinations ramping up. BBB National Programs applauds the herculean efforts by researchers, producers, and regulators to get groundbreaking medical products – both preventative and for treatment – safely into the marketplace to combat the medical crisis.

The commitment we bring to this role is the same we’ve had for 50 years, to be champions for truth in advertising and ensure that consumers get truthful information about products that can support their health during this crisis

 

 

 

Decisions

Decision

National Advertising Review Board Recommends Mint Mobile Discontinue or Modify Certain Claims for its Wireless Service

New York, NY – February 8, 2024 – A panel of the National Advertising Review Board (NARB) recommended that Mint Mobile modify or discontinue cost-per-month pricing promos, discontinue the “cut out the cost of retail service and passed those sweet savings directly to you” claim, and discontinue disparaging social media...

Read the Decision Summary
Decision

National Advertising Review Board Recommends Comcast Discontinue Use of “10G” When Referring to the Name of its Network

New York, NY – February 5, 2024 – A panel of the National Advertising Review Board (NARB) recommended that Comcast discontinue use of the term 10G in the product service name “Xfinity 10G Network” and when 10G is used descriptively to describe the Xfinity network.

Read the Decision Summary
Decision

National Advertising Division Recommends Blueprint Test Preparation Discontinue Certain MCAT Score Improvement Claims

New York, NY – April 22, 2024 – The National Advertising Division recommended Blueprint Test Preparation discontinue certain express and implied claims made in connection with its four MCAT preparation courses, including claims that Blueprint students raise their MCAT scores by 15 or 13 points on average.

Read the Decision Summary
Decision

National Advertising Division Recommends The Princeton Review Discontinue Point Increase Claims for MCAT Test Preparation Services

New York, NY – April 18, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division recommended that The Princeton Review (TPR) discontinue claims that its students “Score a 515+ on the MCAT or add 15 points depending on your starting score. Guaranteed or your money back.”

Read the Decision Summary

 

BBB National Programs provides summaries of all case decisions in the Case Decision Summary library. For the full text of National Advertising Division, National Advertising Review Board, and Children’s Advertising Review Unit decisions, subscribe to the Online Archive. For members of the press, the full text of any BBB National Programs decision is available by emailing the request to press@bbbnp.org

 

 

 

Frequently Asked Questions

 

 

 

 

Contact Us